Structural models of human apolipoprotein A-I: a critical analysis and review

被引:216
作者
Brouillette, CG
Anantharamaiah, GM
Engler, JA
Borhani, DW
机构
[1] Univ Alabama Birmingham, Ctr Biophys Sci & Engn, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Atherosclerosis Res Unit, Birmingham, AL 35294 USA
[3] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA
[4] BASF Biores Corp, Worcester, MA 01605 USA
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS | 2001年 / 1531卷 / 1-2期
基金
美国国家卫生研究院;
关键词
apolipoprotein A-I mutant; high density lipoprotein; exchangeable apolipoprotein; apolipoprotein E; apolipophorin III; molten globule; HDL model; lipid binding; protein folding;
D O I
10.1016/S1388-1981(01)00081-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Human apolipoprotein (apo) A-I has been the subject of intense investigation because of its well-documented antiatherogenic properties. About 70% of the protein found in high density lipoprotein complexes is apo A-I, a molecule that contains a series of highly homologous amphiphatic alpha -helices. A number of significant experimental observations have allowed increasing sophisticated structural models for both the lipid-bound and the lipid-free forms of the apo A-I molecule to be tested critically. It seems clear, for example, that interactions between amphipathic domains in apo A-I may be crucial to understanding the dynamic nature of the molecule and the pathways by which the lipid-free molecule binds to lipid, both in a discoidal and a spherical particle. The state of the art of these structural studies is discussed and placed in context with current models and concepts of the physiological role of apo A-I and high-density lipoprotein in atherosclerosis and lipid metabolism. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:4 / 46
页数:43
相关论文
共 262 条
[1]   Identification of scavenger receptor SR-BI as a high density lipoprotein receptor [J].
Acton, S ;
Rigotti, A ;
Landschulz, KT ;
Xu, SZ ;
Hobbs, HH ;
Krieger, M .
SCIENCE, 1996, 271 (5248) :518-520
[2]  
ANANTHARAMAIAH GM, 1986, METHOD ENZYMOL, V128, P627
[3]   USE OF SYNTHETIC PEPTIDE ANALOGS TO LOCALIZE LECITHIN-CHOLESTEROL ACYLTRANSFERASE ACTIVATING DOMAIN IN APOLIPOPROTEIN-A-I [J].
ANANTHARAMAIAH, GM ;
VENKATACHALAPATHI, YV ;
BROUILLETTE, CG ;
SEGREST, JP .
ARTERIOSCLEROSIS, 1990, 10 (01) :95-105
[4]  
ANANTHARAMAIAH GM, 1991, ADV EXP MED BIOL, V285, P131
[5]  
ANANTHARAMAIAH GM, 1985, J BIOL CHEM, V260, P248
[6]  
Anantharamaiah GM, 1993, AMPHIPATHIC HELIX
[7]   The structural basis of lipid interactions in lipovitellin, a soluble lipoprotein [J].
Anderson, TA ;
Levitt, DG ;
Banaszak, LJ .
STRUCTURE WITH FOLDING & DESIGN, 1998, 6 (07) :895-909
[8]   Pharmacology of apolipoprotein A-I [J].
Andersson, LO .
CURRENT OPINION IN LIPIDOLOGY, 1997, 8 (04) :225-228
[9]   A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis [J].
Asl, KH ;
Liepnieks, JJ ;
Nakamura, M ;
Parker, F ;
Benson, MD .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 257 (02) :584-588
[10]   Hereditary amyloid cardiomyopathy caused by a variant apolipoprotein A1 [J].
Asl, LH ;
Liepnieks, JJ ;
Asl, KH ;
Uemichi, T ;
Moulin, G ;
Desjoyaux, E ;
Loire, R ;
Delpech, M ;
Grateau, G ;
Benson, MD .
AMERICAN JOURNAL OF PATHOLOGY, 1999, 154 (01) :221-227